Harmony Biosciences Holdings (HRMY) Total Current Liabilities (2019 - 2026)

Harmony Biosciences Holdings' Total Current Liabilities history runs 8 years deep, the most recent figure standing at $217.3 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 24.11% year-over-year to $217.3 million; the TTM figure through Mar 2026 stood at $217.3 million (up 24.11% YoY), while the FY2025 annual figure was $252.1 million, up 44.01% from the prior year.
• Total Current Liabilities came in at $217.3 million for Q1 2026 at Harmony Biosciences Holdings, down from $252.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $252.1 million in Q4 2025 to a low of $56.5 million in Q1 2022.
• A 5-year average of $144.0 million and a median of $154.3 million in 2024 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities soared 125.43% in 2022 and grew 4.7% in 2023, its largest moves.
• Harmony Biosciences Holdings' Total Current Liabilities stood at $78.9 million in 2022, then surged by 107.62% to $163.8 million in 2023, then climbed by 6.9% to $175.1 million in 2024, then surged by 44.01% to $252.1 million in 2025, then decreased by 13.8% to $217.3 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $217.3 million, $252.1 million, and $223.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison